

**Final Agenda**  
**47<sup>th</sup> meeting of the Committee for Risk Assessment**

**20 - 23 November 2018**  
**27 - 30 November 2018**

**ECHA Conference Centre (Annankatu 18, Helsinki)**

**Tuesday 20 November starts at 14.00**  
**Friday 30 November ends at 13.00**

**Item 1 – Welcome and Apologies**

**Item 2 – Adoption of the Agenda**

***RAC/A/47/2018***  
***For adoption***

**Item 3 – Declarations of conflicts of interest to the Agenda**

**Item 4 – Appointment of (co-)rapporteurs**

- a) Appointment of (co-)rapporteurs for CLH dossiers, restriction dossiers, authorisation applications and Article 77(3)(c) requests

***For agreement***

**Item 5 – Report from other ECHA bodies and activities**

- a) Report on RAC 46 action points, written procedures and update on other ECHA bodies

***RAC/47/2018/01***  
***(room document)***  
***For information***

- b) RAC workplan for all processes

***For information***

c) General RAC procedures

**RAC/47/2018/02**  
**For discussion**  
**RAC/47/2018/03**  
**For agreement**

d) INTERACT Project

e) RAC Stakeholder Satisfaction Survey 2018

**For information**

### **Item 6 – Requests under Article 77(3)(c)**

**6.1** Copper compounds (M-factor)

**For discussion**

### **Item 7 – Requests under Article 95 (3)**

None

### **Item 8 – Harmonised classification and labelling (CLH)**

**8.1 General CLH issues**

**8.2 CLH dossiers**

#### **A. Hazard classes for agreement without plenary debate (fast-track)**

potassium (oxido-NNO-azoxy)cyclohexane; cyclohexylhydroxydiazene 1-oxide, potassium salt; [K-HDO]: physical hazards, acute toxicity, STOT SE, serious eye damage / eye irritation, skin sensitisation, germ cell mutagenicity, environmental hazards

bis(N-hydroxy-N-nitrosocyclohexylaminato-O,O')copper; bis(N-cyclohexyl-diazanium-dioxy)-copper; [Cu-HDO]: physical hazards, acute toxicity, STOT SE, serious eye damage / eye irritation, skin sensitisation, germ cell mutagenicity

thiencarbazone-methyl (ISO): acute toxicity, STOT SE, skin corrosion / irritation, serious eye damage / eye irritation, STOT RE, germ cell mutagenicity, toxicity to reproduction, environmental hazards

hexythiazox (ISO): environmental hazards

flurochloridone (ISO): physical hazards, acute toxicity, STOT SE, skin corrosion / irritation, serious eye damage / eye irritation, skin sensitisation, STOT RE, germ cell mutagenicity, carcinogenicity, environmental hazards

iprovalicarb (ISO): physical hazards, acute toxicity, skin corrosion / irritation, serious eye damage / eye irritation, skin sensitisation, germ cell mutagenicity, toxicity to reproduction, STOT SE, environmental hazards

2,4-Dinitrophenol: acute oral toxicity

dibenzo[def,p]chrysene: germ cell mutagenicity

mancozeb (ISO): skin sensitisation, environmental hazards

4,5-dichloro-2-octyl-2H-isothiazol-3-one (DCOIT): physical hazards, acute dermal toxicity, germ cell mutagenicity, carcinogenicity, STOT RE

pirimiphos-methyl (ISO): acute toxicity, germ cell mutagenicity, environmental hazards

octhilinone (ISO); [OIT]: acute dermal toxicity, serious eye damage / eye irritation, STOT SE

fluxapyroxad: physical hazards, acute toxicity, STOT SE, skin corrosion / irritation, serious eye damage / eye irritation, germ cell mutagenicity, environmental hazards, hazardous to ozone layer

oxathiapiprolin (ISO): physical hazards, acute toxicity, STOT SE, skin corrosion / irritation, serious eye damage / eye irritation, respiratory or skin sensitisation, STOT RE, germ cell mutagenicity

m-bis(2,3-epoxypropoxy)benzene; resorcinol diglycidyl ether: acute dermal toxicity

Silthiofam (ISO): acute toxicity, skin corrosion / irritation, serious eye damage / eye irritation, skin sensitisation, STOT SE, germ cell mutagenicity, environmental hazards

Pydiflumetofen: environmental hazards [*HH to be confirmed*]

## **B. Hazard classes for agreement with plenary debate**

- 1) potassium (oxido-*NNO*-azoxy)cyclohexane; cyclohexylhydroxydiazene 1-oxide, potassium salt; [K-HDO]
- 2) bis(*N*-hydroxy-*N*-nitrosocyclohexylaminato-*O,O'*)copper; bis(*N*-cyclohexyl-diazonium-dioxy)-copper; [Cu-HDO]
- 3) thien carbazole-methyl (ISO); methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1*H*-1,2,4-triazol-1-yl)carbonylsulfamoyl]-5-methylthiophene-3-carboxylate
- 4) 2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate; [DOTE]
- 5) hexythiazox (ISO); trans-5-(4-chlorophenyl)-*N*-cyclohexyl-4-methyl-2-oxo-3-thiazolidine-carboxamide
- 6) flurochloridone (ISO); 3-chloro-4-(chloromethyl)-1-[3-(trifluoromethyl)phenyl]pyrrolidin-2-one
- 7) iprovalicarb (ISO) isopropyl [(2*S*)-3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl]carbamate
- 8) 2,4-dinitrophenol
- 9) phosphine
- 10) dibenzo[def,p]chrysene
- 11) mancozeb (ISO); manganese ethylenebis(dithiocarbamate) (polymeric) complex with zinc salt
- 12) 2-(4-*tert*-butylbenzyl)propionaldehyde
- 13) 4,5-dichloro-2-octyl-2*H*-isothiazol-3-one (DCOIT)
- 14) pirimiphos-methyl (ISO)
- 15) octhilinone (ISO); 2-octyl-2*H*-isothiazol-3-one; [OIT]
- 16) 3-(difluoromethyl)-1-methyl-*N*-(3',4',5'-trifluorobiphenyl-2-yl)pyrazole-4-carboxamide; fluxapyroxad
- 17) oxathiapiprolin (ISO); 1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-

- oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone
- 18) *m*-bis(2,3-epoxypropoxy)benzene
- 19) silthiofam (ISO); *N*-allyl-4,5-dimethyl-2-(trimethylsilyl)thiophene-3-carboxamide
- 20) *N*-methoxy-*N*-[1-methyl-2-(2,4,6-trichlorophenyl)-ethyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide; pydiflumetofen
- 21) hexyl 2-(1-(diethylaminohydroxyphenyl)methanoyl) benzoate
- 22) lead

***For discussion and adoption***

## **Item 9 – Restrictions**

### **9.1 Restriction Annex XV dossiers**

- a) Conformity check and key issues discussion

- 1) *N,N*-dimethylformamide
- 2) Five cobalt salts

***For agreement***

- b) Opinion development

- 1) Plastic and rubber granulates containing PAHs– first draft opinion

***For discussion***

- 2) Substances used in tattoo inks and permanent make-up – final draft opinion

***For adoption***

## **Item 10 – Authorisation**

### **10.1 General authorisation issues**

- a) Update on incoming/future applications

***For information***

- b) AfA A-listing draft procedure

***RAC/47/2018/04***

***For agreement***

### **10.2. Authorisation applications**

- a) Agreement on draft opinions

1. CT\_MAHLE (1 use)

2. CT\_Doosan (1 use)

***For discussion and agreement***

- b) Adoption of final opinions

1. CT\_Hapoc\_2 (1 use)

***For discussion and adoption***

### **10.3. Review reports**

- a) Discussion on key issues

1. RR1\_TCE\_Spolana

***For discussion***

- c) Adoption of final opinions

- a. RR1\_DEHP\_PP (2 uses)

***For discussion and adoption***

<b>Item 11 – AOB</b>
----------------------

<b>Item 12 – Action points and main conclusions of RAC-47</b>
---

Table with Conclusions and Action points from RAC-47

***For adoption***